Gene therapy applications for spine fusion

Spine

Volumn 28, Issue 15 SUPPL., 2003, Pages

  Cha, Charles W ^b   Boden, Scott D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Gene therapy; Growth factors; LMP 1; Spine fusion

Indexed keywords

BETA GLUCOSIDASE; DNA; GROWTH FACTOR; LIM MINERALIZATION PROTEIN 1; LIM PROTEIN; NUCLEIC ACID; OSTEOGENIC PROTEIN 1; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RNA; UNCLASSIFIED DRUG;

AUTOGRAFT; DNA DETERMINATION; DOSE RESPONSE; GENE THERAPY; GENETIC DISORDER; GENETIC MANIPULATION; HUMAN; IN VITRO STUDY; MINIMALLY INVASIVE SURGERY; NONVIRAL GENE DELIVERY SYSTEM; NUCLEIC ACID TRANSPORT; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SPINE DISEASE; SPINE FUSION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

EID: 0041566591     PISSN: 03622436     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.brs.0000076902.64395.c3     Document Type: Review

References (98)

1. Depalma AF, Rothman RH. The nature of pseudoarthrosis. Clin Orthop 1968;59:113-8.
2. Steinmann JC, Herkowitz HN. Pseudarthrosis of the spine. Clin Orthop 1992;80-90.
3. Boden SD. The biology of posterolateral lumbar spinal fusion. Orthop Clin North Am 1998;29:603-19.
4. Boden SD, Sumner DR. Biologic factors affecting spinal fusion and bone regeneration. Spine 1995;20:102S-2S.
5. Evans JH. Biomechanics of lumbar fusion. Clin Orthop 1985;193:38-46.
6. Hurley LA, Stinchfield FE, Bassett AL, et al. The role of soft tissues in osteogenesis: An experimental study of canine spine fusions. J Bone Joint Surg 1959;41:1243-54.
7. Perren SM. Physical and biological aspects of fracture healing with special reference to internal fixation. Clin Orthop 1979;138:175-96.
8. Perren SM, Matter P, Ruedi R, et al. Biomechanics of fracture healing after internal fixation. Surg Annu 1975;7:361-90.
9. Hooper GJ, Keddell RG, Penny ID. Conservative management or closed nailing for tibial fractures: A randomized prospective trial. J Bone Joint Surg [Br] 1991;73:83-5.
10. Bouchard JA, Koka A, Bensusan JS, et al. Effects of irradiation on posterior spinal fusions: A rabbit model. Spine 1994;19:1836-41.
11. Brown CW, Orme TJ, Richardson HD. The rate of pseudoarthrosis (surgical nonunion) in patients who are smokers and patients who are nonsmokers: A comparison study. Spine 1986;11:942-3.
12. Daftari TK, Whitesides TE, Heller JG, et al. Nicotine on the revascularization of bone graft: An experimental study in rabbits. Spine 1994;19:904-11.
13. Dimar JR, Ante WA, Zhang P, et al. The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 1996;20:1870-6.
14. Emery SE, Brazinski MS, Koka A, et al. The biological and biomechanical effects of irradiation on anterior spinal bone grafts: A canine model. J Bone Joint Surg [Am] 1994;76:540-8.
15. Hanley EN, Levy JA. Surgical treatment of isthmic lumbosacral spondylolisthesis: Analysis of variables affecting results. Spine 1989;14:48-50.
16. Ho ML, Chang JK, Wang GJ. Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop 1995;313:270-8.
17. Hogevold HE, Grogaard B, Reikeras O. Effects of short-term treatment with corticosteroids and indomethacin on bone healing. Acta Orthop Scand 1992;63:607-11.
18. Silcox DH, Daftari T, Boden SD, et al. The effect of nicotine on spinal fusion. Spine 1995;20:1549-53.
19. Zdeblick TA. A prospective, randomized study of lumbar fusion: Preliminary results. Spine 1993;18:983-91.
20. Bridwell KH, Sedgewick TA, O'Brien MF, et al. The role of fusion and instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Dis 1993;6:461-72.
21. Dwyer AF. The use of electrical current stimulation in spinal fusion. Orthop Clin North Am 1975;6:265-79.
22. Kahanovitz N, Arnoczky SP. The efficacy of direct current electrical stimulation to enhance canine spinal fusions. Clin Orthop 1990;251:295-9.
23. Kane WJ. Direct current electrical bone growth stimulation for spinal fusion. Spine 1988;13:363-5.
24. Nagel DA, Kramers PC, Rahn BA, et al. A paradigm of delayed union and nonunion in the lumbosacral joint: A study of motion and bone grafting of the lumbosacral spine in sheep. Spine 1991;16:553-9.
25. Mcguire RA, Amundson GM. The use of primary internal fixation in spondylolisthesis. Spine 1993;18:1662-72.
26. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996;334:1185-7.
27. Fernyhough JC, Schimandle JH, Weigle MC, et al. Donor site pain complicating bone graft harvesting from the posterior iliac crest for spinal fusion. Spine 1992;17:1474-80.
28. Laurie SWS, Kaban LB, Muttiken JB, et al. Donor-site morbidity after harvesting rib and iliac bone. Plast Reconstr Surg 1984;73:933-8.
29. Prolo DJ, Rodrigo JJ. Contemporary bone graft physiology and surgery. Clin Orthop 1985;200:322-42.
30. Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma 1989;3:192-5.
31. Bolander ME. Regulation of fracture repair by growth factors. Proc Soc Exp Biol Med 1992;200:165.
32. Bourque WT, Gross M, Hall BK. Expression of four growth factors during fracture repair. Int J Dev Biol 1993;37:573-9.
33. Sakou T. Bone morphogenetic proteins: From basic studies to clinical approaches. Bone 1998;22:591-603.
34. Trippel SB. Potential role of insulin-like growth factors in fracture healing. Clin Orthop 1998;355:8301:S301-13.
35. Aspenberg P, Wang E, Thorngren KG. Bone morphogenetic protein induces. bone in the squirrel monkey, but bone matrix does not. Acta Orthop Scand 1992;63:619-22.
36. Scully SP. Gene therapy: Clinical considerations. Clin Orthop 2000;S55-8.
37. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992;176:1125-35.
38. Khan SN, Hidaka C, Sandhu HS, et al. Orthop Clin North Am 2000;31:473-84.
39. Knoell DL, Yiu IM. Human gene therapy for hereditary diseases: A review of trials. Am J Health Syst Pharm 1998;55:899-904.
40. Batshaw ML, Wilson JM, Raper S, et al. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Hum Gene Ther 1999;10:2419-37.
41. Ludwig SC, Boden SD. Osteoinductive bone graft substitutes for spinal fusion. Orthop Clin North Am 1999;30:635-45.
42. Burchardt H. The biology of bone graft repair. Clin Orthop 1983;174:28-42.
43. Urist MR. Bone formation by autoinduction. Science 1965;150:893-9.
44. Helm GA, Alden TD, Sheehan JP, et al. Bone morphogenetic proteins and bone morphogenetic protein gene therapy in neurological surgery: A review. Neurosurgery 2000;46:1213-22.
45. Sandhu HS, Boden SD. Biologic enhancement of spinal fusion. Orthop Clin North Am 1998;29:621-31.
46. Boden SD, Schimandle JH, Hutton WC. Lumbar intertransverse-process spinal arthrodesis with use of a bovine bone-derived osteoinductive protein. A preliminary report. J Bone Joint Surg [Am] 1995;77:1404-17.
47. Johnson EE, Urist MR, Finerman GAM. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein: A preliminary report. Clin Orthop 1988;236:249-57.
48. Sandhu HS, Lane JM, Shamie A, et al. Human spinal fusions with native bone morphogenetic protein: Short-term and 10 year follow-up. Trans Am Acad Orthop Surg 1997;
49. Sandhu HS, Kanim LEA, Kabo JM, et al. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine 1996;21:2115-22.
50. Cook SD, Dalton JE, Tan EH, et al. In vivo evaluation of recombinant human osteogenic protein (rhOP-1.) implants as a bone graft substitute for spinal fusions. Spine 1994;19:1655-63.
51. Schimandle JH, Boden SD, Hutton WC. Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 1995;20:1326-37.
52. Boden SD, Schimandle JH, Hutton WC. Volvo Award in basic sciences. The use of an osteoinductive growth factor for lumbar spinal fusion. Part II: Study of dose, carrier, and species. Spine 1995;20;2633-44.
53. Boden SD, Zdeblick TA, Sandhu HS, et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: A preliminary report. Spine 2000;25:376-81.
54. Martin GJ Jr, Boden SD, Marone MA, et al. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: Important lessons learned regarding dose, carrier, and safety. J Spinal Disord 1999;12:179-86.
55. Palmer TD, Rosman GJ, Osborne WR, et al. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991;88:1330-4.
56. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994;91:2567-71.
57. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 1991;88:4626-30.
58. Evans CH, Robbins PD. Possible orthopaedic applications of gene therapy. J Bone Joint Surg [Am] 1995;77:1103-14.
59. Furth PA, St Onge L, Boger H, et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 1994;91:9302-6.
60. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-51.
61. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-9.
62. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997;8:803-15.
63. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 1996;56:4614-9.
64. Lian JB, Stein GS, Stewart C, et al. Osteocalcin: Characterization and regulated expression of the rat gene. Connect Tissue Res 1989;21:61-8.
65. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998;80:35-47.
66. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are ire actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-42.
67. Mulligan RC. Gene transfer and gene therapy. Principles, prospects and perspective. In: Lindsten J, Pettersson U, eds. Etiology of Human Disease at the DNA Level. New York: Raven Press, 1991:143-89.
68. Bonnekoh B, Greenhalgh DA, Bundman DS, et al. Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. J Invest Dermatol 1996;106:1163-8.
69. Kozarsky KF, Jooss K, Donahee M, et al. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996;13:54-62.
70. Zabner J, Couture LA, Gregory RJ, et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75:207-16.
71. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-32.
72. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995;270:404-10.
73. Mack CA, Song WR, Carpenter H, et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997;8:99-109.
74. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11.
75. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990;87:2211-5.
76. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991;10:3941-50.
77. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-54.
78. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994;5:793-801.
79. Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994;91:9519-23.
80. Sikes ML, O'Malley BW Jr, Finegold MJ, et al. In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum Gene Ther 1994;5:837-44.
81. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
82. Fang J, Zhu YY, Smiley E, et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci USA 1996;93:5753-8.
83. Goldstein SA, Bonadio J. Potential role for direct gene transfer in the enhancement of fracture healing. Clin Orthop 1998;S154-62.
84. Felgner PL, Gadek TR, Holm M, et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7.
85. Perales JC, Ferkol T, Beegen H, et al. Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994;91:4086-90.
86. Benn SI, Whitsitt JS, Broadley KN, et al. Particle-mediated gene transfer with transforming growth factor-beta1 cDNAs enhances wound repair in rat skin. J Clin Invest 1996;98:2894-902.
87. Eming SA, Whitsitt JS, He L, et al. Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol 1999;112:297-302.
88. Jiao S, Cheng L, Wolff JA, et al. Particle bombardment-mediated gene transfer and expression in rat brain tissues. Biotechnology [NY] 1993;11:497-502.
89. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993;90:4455-9.
90. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982;1:327-41.
91. Riew KD, Wright NM, Cheng S, et al. Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 1998;63:357-60.
92. Alden TD, Pittman DD, Beres EJ, et al. Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. J Neurosurg 1999;90:109-14.
93. Helm GA, Alden TD, Beres EJ, et al. Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg 2000;92S:191-6.
94. Boden SD, Liu Y, Hair GA, et al. LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology 1998;139:5125-34.
95. Boden SD, Titus L, Hair G, et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine 1998;23:2486-92.
96. Viggeswarapu M, Boden SD, Liu Y, et al. Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J Bone Joint Surg [Am] 2001;83:364-76.
97. Cheng S-L, Lou J, Wright NM, et al. In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene. Calcif Tissue Int 2001;68:87-94.
98. West JL III, Bradford DS, Ogilvie JW. Results of spinal arthrodesis with pedicle screw-plate fixation. J Bone Joint Surg [Am] 1991;73:1179-84.